Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged ≥ 18 years.~2. Patients with Stage 1 NK defined by the Mackie criteria~Exclusion Criteria:~1. Evidence of an active ocular infection (bacterial, viral, protozoal) in either eye.~2. Have current or history of conditions that may confound the study data including but not limited to Ocular Cicatricial Pemphigoid (OCP), Graft Versus Host Disease (GVHD), neuromyelitis optica, uncontrolled dry eye, and Steven Johnson's syndrome.~3. History of severe systemic allergy or severe ocular allergy (including seasonal conjunctivitis expected during the subject's participation in the trial) or chronic conjunctivitis and/or keratitis other than dry eye disease.~4. Patients with severe vision loss with no potential for visual improvement in the study eye, in the opinion of the investigator, or if the subject is deemed legally blind.~5. Ocular surgery or elective ocular surgery expected during participation in the trial.~6. Patients with eyelid abnormality that may alter eyelid function including but not limited to Blepharospasm, Cerebrovascular accident, entropion, ectropion, floppy lid syndrome.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).